IngentaConnect Platelet Protective Effect of TAK-029, A Novel Glycoprotein IIb/I...

Authors: Kawahito, Koji¹; Fujimura, Akio²; Kobayashi, Eiji²; Misawa, Yoshio¹; Fuse, Katsuo¹

Source: Artificial Organs, Volume 22, Number 4, April 1998 , pp. 348-352(5)

Abstract:

Previous studies have indicated that exposure of fibrinogen receptors associated with the glycoprotein IIb/IIIa complex contributes to platelet loss during cardiopulmonary bypass. TAK-029 is a newly developed reversible, nonpeptide inhibitor of platelet glycoprotein IIb/IIIa receptors. In this study, we tested the platelet preserving effect of TAK-029 in an in vitro model. The methods included the comparison of the release of β-thromboglobulin (β-TG) between a TAK-029 group (n = 5) and a control group (n = 5) in a mock circulation under a shear force generated by a centrifugal pump. To evaluate the degree of β-TG release, Δβ-TG/ΔT was calculated where Δβ-TG is the increase in βTG and ΔT is the time. The results showed that the value of Δβ-TG/ΔT in the TAK-029 group was significantly lower than it was in the control group (4.22 ± 0.27 × 10² ng/ml vs. 7.33 ± 0.66 × 10² ng/ml, respectively). In conclusion, TAK-029 reduced the platelet activation under the shear forces of an in vitro model, suggesting that TAK-029 is a potential candidate for platelet protection during cardiopulmonary bypass.

Keywords: Platelet; Glycoprotein IIb/IIIa; Cardiopulmonary bypass

Document Type: Original article

DOI: 10.1046/j.1525-1594.1998.06050.x

Affiliations: 1: Department of Cardiovascular Surgery, Jichi Medical School, Tochigi, Japan 2: Department of Clinical Pharmacology, Jichi Medical School, Tochigi, Japan

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.16 plus tax Refund Policy

Platelet Protective Effect of TAK-029, A Novel Glycoprotein IIb/IIIa Antagonist: An In Vitro Study